ロード中...
COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection
In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared a global pandemic by the World Health Organization (WHO). The clinical course of the disease is unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to acute respiratory dist...
保存先:
| 出版年: | Pharmaceuticals (Basel) |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7830835/ https://ncbi.nlm.nih.gov/pubmed/33477294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14010071 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|